GlassScriptPhysician profile
Charles David Pumphrey
NPI 1043270531
$4,073.42
in general payments reported to CMS, 2019-2025
27 companies · $554 in 2025
The $554 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $667 · 2021: $763 · 2022: $656 · 2023: $480 · 2024: $488 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $886.76 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $452.44 | 2019-2025 | Onyda Xr |
| Pfizer INC. | $354.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $251.71 | 2019-2021 | |
| Sanofi Pasteur INC. | $241.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $213.81 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $209.19 | 2020-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $202.76 | 2021-2024 | Qelbree |
| Corium, LLC | $198.90 | 2021-2024 | Azstarys, Azstarys |
| Sobi, INC | $173.08 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $168.76 | 2025 | Jornay Pm |
| Kaleo, INC. | $98.48 | 2019-2021 | |
| Glaxosmithkline, LLC. | $93.03 | 2019-2022 | |
| Neos Therapeutics, LP | $83.33 | 2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Mylan Pharmaceuticals INC. | $81.07 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $73.10 | 2023-2024 | Flumist Quadrivalent |
| E.R. Squibb & Sons, L.L.C. | $58.37 | 2019 | |
| Alk-Abello, INC | $56.67 | 2025 | Neffy |
| Vertical Pharmaceuticals, LLC | $37.97 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $32.00 | 2020-2022 | |
| Sarepta Therapeutics, INC. | $17.26 | 2021 | |
| Genentech USA, INC. | $16.00 | 2020 | |
| Phadia US INC. | $15.40 | 2022 | |
| Seqirus USA INC | $15.22 | 2021 | |
| Adlon Therapeutics L.P. | $14.45 | 2021 | |
| Lnhc, INC | $14.25 | 2025 | Zelsuvmi |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Pumphrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.